In vivo imaging of CD8⁺ T cells in metastatic cancer patients: first clinical experience with simultaneous [⁸⁹Zr]Zr-Df-IAB22M2C PET/MRI.

ABSTRACT: Aim/Introduction: Despite the spectacular success of immune checkpoint inhibitor therapy (ICT) in patients with metastatic cancer, only a limited proportion of patients benefit from ICT. CD8⁺ cytotoxic T cells are important gatekeepers for the therapeutic response to ICT and are able to recognize MHC class I-dependent tumor antigens and destroy tumor cells. The radiolabeled minibody [⁸⁹Zr]Zr-Df-IAB22M2C has a high affinity for human CD8⁺ T cells and was successfully tested in a phase I study. Here, we aimed to gain the first clinical PET/MRI experience with the noninvasive assessment of the CD8⁺ T-cell distribution in cancer patients by in vivo [⁸⁹Zr]Zr-Df-IAB22M2C with a distinct focus of identifying potential signatures

SUBMITTER: Schwenck J 

PROVIDER: S-EPMC10196830 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature